Case Study: In-License P&MA Assessment in Migraine

Project Objective

• A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines

• Windrose was asked to carry out due diligence on the value, price and market access potential of the new anti-CGRP to inform decision-making, including options to address potential competitor strategies

Windrose Approach

• We assessed the current migraine pricing and market access landscape across the US, Europe, and Japan, and potential future changes given entrance of multiple anti-CGRPs

• We reviewed potential analogs to hypothesize payer outcomes for the client’s product

• We conducted in-depth interviews with national and regional payers & KOLs to assess key value drivers and barriers for the anti-CGRP competitors

• In the US, we provided recommendations on the level of rebates required to maximize revenue

  • Identified price and utilization trade-offs, when considering potential payer restrictions and level of patient copay

  • Evaluated impact on volume / prescribing if competitor attempts to undercut on price

Impact

• The final deliverable included insights on payer willingness and ability to adopt innovative contracting, and its impact on price, access, prescribing, time to coverage decisions

• Core evidence requirements / value drivers for reimbursement were identified as well as other market access / barriers and possible strategies to minimize them

• Our recommendations helped to inform whether the client should enter a partnership with one of the companies developing an anti-CGRP

• The client proceeded with an optimized pricing strategy and early payer engagement strategies to facilitate pricing / contracting discussion and improve access

Price strategies, Windrose Consulting group